Capsoni F, Bonara P, Minonzio F, Ongari A M, Colombo G, Rizzardi G P, Zanussi C
Istituto di Medicina Interna, University of Milan, Italy.
J Clin Lab Immunol. 1991 Mar;34(3):115-24.
The recombinant (r) cytokines interferon-gamma (rIFN-gamma), granulocyte/macrophage-colony stimulating factor (rGM-CSF) and tumor necrosis factor-alpha (rTNF-alpha) all activate neutrophils. The aim of this work was to determine the effect of these cytokines on neutrophil Fc-receptor (FcR)-mediated phagocytosis and membrane expression of FcR, particularly FcRII and FcRIII. A short treatment (greater than or equal to 15 min) of neutrophils with rGM-CSF and rTNF-alpha at concentrations greater than or equal to 62.5 U/ml significantly increased their ability to bind and phagocytize IgG-coated erythrocytes (EA). Both cytokines also showed more enhancing activity when suboptimally sensitized EA were used for binding and ingestion assays. A similar treatment of neutrophils with rIFN-gamma at doses up to 500 U/ml was ineffective. The effect of rGM-CSF and rTNF-alpha was blocked by a monoclonal anti-GM-CSF antibody and by a polyclonal anti-TNF-alpha antibody respectively, thus establishing that the cytokines were responsible for the activity of the recombinant preparations. The cytokine-induced enhancement of FcR-mediated phagocytosis did not correlate with an enhancement of FcRII membrane expression on treated neutrophils; rGM-CSF significantly increased FcRIII expression, but rTNF-alpha and rIFN-gamma were both ineffective in this respect. Since different roles of FcRII and FcRIII have been reported on ligand binding and ingestion, we also studied the effect of rGM-CSF and rTNF-alpha on the functional properties of these FcR, using specific monoclonal antibodies (mAbs). In the blocking experiments the pretreatment of neutrophils with rGM-CSF and rTNF-alpha did not modify the blocking properties of either anti-FcRII or anti-FcRIII mAbs, suggesting that cytokine-pretreatment does not affect the individual contribution of each type of FcR to ligand binding and internalization. Our data point to a new activity for both rGM-CSF and rTNF-alpha in augmenting FcR-mediated phagocytosis on neutrophils, but the mechanism of this enhancement remains to be elucidated.
重组(r)细胞因子γ干扰素(rIFN-γ)、粒细胞/巨噬细胞集落刺激因子(rGM-CSF)和肿瘤坏死因子-α(rTNF-α)均可激活中性粒细胞。本研究的目的是确定这些细胞因子对中性粒细胞Fc受体(FcR)介导的吞噬作用及FcR膜表达的影响,尤其是FcRII和FcRIII。用浓度大于或等于62.5 U/ml的rGM-CSF和rTNF-α对中性粒细胞进行短时间(大于或等于15分钟)处理,可显著增强其结合和吞噬IgG包被红细胞(EA)的能力。当使用次优致敏的EA进行结合和摄取试验时,这两种细胞因子也表现出更强的增强活性。用剂量高达500 U/ml的rIFN-γ对中性粒细胞进行类似处理则无效。rGM-CSF和rTNF-α的作用分别被单克隆抗GM-CSF抗体和多克隆抗TNF-α抗体阻断,从而确定细胞因子是重组制剂活性的原因。细胞因子诱导的FcR介导的吞噬作用增强与处理后的中性粒细胞上FcRII膜表达的增强无关;rGM-CSF显著增加FcRIII表达,但rTNF-α和rIFN-γ在这方面均无效。由于FcRII和FcRIII在配体结合和摄取方面具有不同作用,我们还使用特异性单克隆抗体(mAb)研究了rGM-CSF和rTNF-α对这些FcR功能特性的影响。在阻断实验中,用rGM-CSF和rTNF-α预处理中性粒细胞不会改变抗FcRII或抗FcRIII mAb的阻断特性,表明细胞因子预处理不会影响每种类型的FcR对配体结合和内化的单独作用。我们的数据表明rGM-CSF和rTNF-α在增强中性粒细胞FcR介导的吞噬作用方面具有新的活性,但这种增强的机制仍有待阐明。